Wall Street brokerages expect that Crispr Therapeutics AG (NASDAQ:CRSP) will post $59.43 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Crispr Therapeutics’ earnings. The highest sales estimate is $76.70 million and the lowest is $14.30 million. Crispr Therapeutics reported sales of $120,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 49,425%. The firm is expected to report its next earnings results on Monday, February 24th.
On average, analysts expect that Crispr Therapeutics will report full-year sales of $272.00 million for the current year, with estimates ranging from $226.90 million to $289.27 million. For the next fiscal year, analysts anticipate that the company will report sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million.
Several equities research analysts recently weighed in on the company. Oppenheimer lifted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, November 25th. Goldman Sachs Group increased their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a report on Tuesday, November 19th. Finally, William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $69.54.
In related news, President Rodger Novak sold 33,618 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 over the last 90 days. Corporate insiders own 21.40% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Benjamin Edwards Inc. grew its holdings in shares of Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Crispr Therapeutics by 13.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after purchasing an additional 343 shares during the last quarter. Traynor Capital Management Inc. boosted its stake in Crispr Therapeutics by 5.8% during the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock valued at $280,000 after purchasing an additional 375 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in shares of Crispr Therapeutics by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after purchasing an additional 386 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. increased its holdings in shares of Crispr Therapeutics by 7.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock worth $331,000 after purchasing an additional 467 shares in the last quarter. Hedge funds and other institutional investors own 49.81% of the company’s stock.
Shares of NASDAQ:CRSP opened at $73.13 on Wednesday. The firm has a market capitalization of $4.04 billion, a P/E ratio of -21.26 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock has a 50 day moving average price of $52.76 and a 200-day moving average price of $46.89. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Initial Public Offering (IPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com